SG11201608896QA - Stable compositions of neuroactive peptides - Google Patents
Stable compositions of neuroactive peptidesInfo
- Publication number
- SG11201608896QA SG11201608896QA SG11201608896QA SG11201608896QA SG11201608896QA SG 11201608896Q A SG11201608896Q A SG 11201608896QA SG 11201608896Q A SG11201608896Q A SG 11201608896QA SG 11201608896Q A SG11201608896Q A SG 11201608896QA SG 11201608896Q A SG11201608896Q A SG 11201608896QA
- Authority
- SG
- Singapore
- Prior art keywords
- stable compositions
- neuroactive peptides
- neuroactive
- peptides
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461984216P | 2014-04-25 | 2014-04-25 | |
| PCT/US2015/027745 WO2015164859A1 (en) | 2014-04-25 | 2015-04-27 | Stable compositions of neuroactive peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201608896QA true SG11201608896QA (en) | 2016-11-29 |
Family
ID=54333349
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201608896QA SG11201608896QA (en) | 2014-04-25 | 2015-04-27 | Stable compositions of neuroactive peptides |
| SG10201803880TA SG10201803880TA (en) | 2014-04-25 | 2015-04-27 | Stable compositions of neuroactive peptides |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201803880TA SG10201803880TA (en) | 2014-04-25 | 2015-04-27 | Stable compositions of neuroactive peptides |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20170049844A1 (en) |
| EP (2) | EP3134103B1 (en) |
| JP (1) | JP6702883B2 (en) |
| KR (1) | KR20160144499A (en) |
| CN (2) | CN106535913B (en) |
| AU (2) | AU2015249222A1 (en) |
| BR (1) | BR112016024841A2 (en) |
| CA (1) | CA2946413A1 (en) |
| CL (1) | CL2016002704A1 (en) |
| IL (1) | IL248433B (en) |
| RU (1) | RU2716164C2 (en) |
| SG (2) | SG11201608896QA (en) |
| UA (1) | UA122204C2 (en) |
| WO (1) | WO2015164859A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111670041A (en) | 2017-12-05 | 2020-09-15 | 诺雷克斯股份有限公司 | Combination of NMDA receptor modulators (lapatin) for use in combination therapy (sleep disorders or central nervous system disorders) |
| WO2020146878A1 (en) * | 2019-01-11 | 2020-07-16 | Naurex Inc. | Salt and crystalline forms of rapastinel |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4086196A (en) | 1975-03-28 | 1978-04-25 | Armour Pharmaceutical Company | Parathyroid hormone |
| NZ212207A (en) * | 1984-05-31 | 1991-07-26 | Genentech Inc | Recombinant lymphotoxin |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| HN1998000106A (en) * | 1997-08-01 | 1999-01-08 | Pfizer Prod Inc | PARENTERAL COMPOSITIONS OF ALATROFLAXACINO |
| JP2008519007A (en) * | 2004-11-04 | 2008-06-05 | ノボ ノルディスク アクティーゼルスカブ | Peptides for use in the treatment of obesity |
| KR20080027253A (en) * | 2005-06-16 | 2008-03-26 | 미리어드 제네틱스, 인크. | Pharmaceutical compositions and use thereof |
| AU2007258325B2 (en) * | 2006-06-12 | 2013-02-21 | Merck Sharp & Dohme Corp. | Pharmaceutical formulations and compositions of a selective antagonist of either CXCR2 or both CXCR1 and CXCR2 and methods of using the same for treating inflammatory disorders |
| WO2011003064A2 (en) * | 2009-07-02 | 2011-01-06 | Naurex, Inc. | Methods of treating neuropathic pain |
| MX2012009388A (en) * | 2010-02-11 | 2012-10-01 | Univ Northwestern | Secondary structure stabilized nmda receptor modulators and uses thereof. |
| US9321848B2 (en) * | 2011-06-28 | 2016-04-26 | Leukocare Ag | Method for preventing the unfolding of a (poly)peptide and/or inducing the (re-)folding of a (poly)peptide |
| EP2572736A1 (en) * | 2011-09-23 | 2013-03-27 | Spago Imaging AB | Nanostructures comprising manganese |
| WO2013188465A2 (en) * | 2012-06-13 | 2013-12-19 | Arizona Board Of Regents, For And On Behalf Of, Arizona State University | Pharmaceutical compositions and methods for treating drug addiction and preventing a drug relapse |
| US20140050789A1 (en) * | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
-
2015
- 2015-04-27 AU AU2015249222A patent/AU2015249222A1/en not_active Abandoned
- 2015-04-27 UA UAA201611031A patent/UA122204C2/en unknown
- 2015-04-27 CN CN201580021447.XA patent/CN106535913B/en not_active Expired - Fee Related
- 2015-04-27 SG SG11201608896QA patent/SG11201608896QA/en unknown
- 2015-04-27 CN CN202110038414.3A patent/CN112716890A/en active Pending
- 2015-04-27 US US15/306,731 patent/US20170049844A1/en not_active Abandoned
- 2015-04-27 EP EP15783438.3A patent/EP3134103B1/en active Active
- 2015-04-27 BR BR112016024841A patent/BR112016024841A2/en active Search and Examination
- 2015-04-27 KR KR1020167032777A patent/KR20160144499A/en not_active Application Discontinuation
- 2015-04-27 RU RU2016144342A patent/RU2716164C2/en active
- 2015-04-27 SG SG10201803880TA patent/SG10201803880TA/en unknown
- 2015-04-27 EP EP20151685.3A patent/EP3689362A1/en not_active Withdrawn
- 2015-04-27 JP JP2016564190A patent/JP6702883B2/en active Active
- 2015-04-27 CA CA2946413A patent/CA2946413A1/en not_active Abandoned
- 2015-04-27 WO PCT/US2015/027745 patent/WO2015164859A1/en active Application Filing
-
2016
- 2016-10-20 IL IL248433A patent/IL248433B/en active IP Right Grant
- 2016-10-24 CL CL2016002704A patent/CL2016002704A1/en unknown
-
2020
- 2020-01-23 US US16/751,187 patent/US20200254050A1/en not_active Abandoned
- 2020-11-27 AU AU2020277278A patent/AU2020277278A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3134103A4 (en) | 2017-12-27 |
| CN112716890A (en) | 2021-04-30 |
| WO2015164859A1 (en) | 2015-10-29 |
| US20200254050A1 (en) | 2020-08-13 |
| JP6702883B2 (en) | 2020-06-03 |
| AU2015249222A1 (en) | 2016-11-17 |
| CN106535913B (en) | 2021-01-26 |
| CA2946413A1 (en) | 2015-10-29 |
| KR20160144499A (en) | 2016-12-16 |
| CN106535913A (en) | 2017-03-22 |
| AU2020277278A1 (en) | 2021-01-07 |
| RU2016144342A (en) | 2018-05-28 |
| RU2716164C2 (en) | 2020-03-06 |
| EP3134103B1 (en) | 2020-01-15 |
| JP2017514817A (en) | 2017-06-08 |
| EP3689362A1 (en) | 2020-08-05 |
| BR112016024841A2 (en) | 2017-10-24 |
| EP3134103A1 (en) | 2017-03-01 |
| IL248433B (en) | 2020-03-31 |
| US20170049844A1 (en) | 2017-02-23 |
| IL248433A0 (en) | 2016-12-29 |
| RU2016144342A3 (en) | 2018-11-13 |
| UA122204C2 (en) | 2020-10-12 |
| SG10201803880TA (en) | 2018-07-30 |
| CL2016002704A1 (en) | 2017-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1225655A1 (en) | Pharmaceutical compositions comprising azd9291 | |
| GB201618482D0 (en) | Pharmaceutical compositions | |
| GB201419257D0 (en) | Pharmaceutical compositions | |
| GB201409348D0 (en) | Perfume compositions | |
| PT3102555T (en) | Compositions of compounds and uses thereof | |
| IL249553A0 (en) | Pharmaceutical compositions | |
| ZA201606075B (en) | Pharmaceutical compositions of sitagliptin | |
| PT3215132T (en) | Methods of administering amantadine compositions | |
| GB201408167D0 (en) | Compositions | |
| IL252977B (en) | Compositions comprising tshr peptides | |
| IL250817A0 (en) | Pharmaceutical compositions | |
| IL248433B (en) | Stable compositions of neuroactive peptides | |
| PL3240529T3 (en) | Stable pharmaceutical compositions comprising micafungin | |
| EP3207936A4 (en) | Stable peptide composition | |
| PL3200772T3 (en) | Pharmaceutical compositions comprising alpelisib | |
| SG11201609739UA (en) | Derivatives of dolaproine-dolaisoleuine peptides | |
| GB201504211D0 (en) | Use of peptides | |
| GB201418410D0 (en) | use of compositions of matter | |
| SG2014014872A (en) | Pharmaceutical compositions | |
| GB201415634D0 (en) | Novel compositions | |
| GB201418500D0 (en) | Therapeutic compositions | |
| GB201418299D0 (en) | Therapeutic compositions | |
| GB201419849D0 (en) | Compositions | |
| GB201408432D0 (en) | Pharmaceutical compositions | |
| GB201412359D0 (en) | Composition of objects |